International: +1-(617)-969-5452 Toll Free: 800-370-5452
Stable, small uniform particle sizes with tight distributions is crucial for sterile filtration, increasing bioavailability and stability for pharmaceutical industry. This is vital in producing successful Vaccine Adjuvants which can be used in the fight against seasonal flu and pandemic influenza.
Let us use our collective 90 years of applications development and machine engineering experience to help drive your product to market as quickly as possible.
Microfluidics technology delivers not just highest shear forces, but also applies it uniformly to ensure that every mL of material undergoes the same high shear rates whether it is 1mL at a time up to many liters per minute to achieve nanoemulsions with tight distribution.
Microfluidizer® processors are designed to be simple to use and clean with the option of conforming to cGMP requirements.
Nanoemulsions are increasingly important drug delivery mechanisms. Microfluidizer® technology has been proven to be ideal in the formulation of sterile injectable, insoluble drugs. It helps to overcome the limitations of solubility, stability and sterilization that are inherent in conventional emulsion manufacturing techniques.
Microfluidics has been working in collaboration on Vaccine Adjuvants with the Infectious Disease Research Institute (IDRI).
Nanoemulsions with small particle sizes increase bioavailability and enable targeting (e.g., cancer drugs getting past the blood/brain barrier and inside cells).
In manufacturing nanoemulsion vaccine adjuvants we found that emulsions obtained from a Microfluidizer® processor were 18% – 55% smaller than the homogenized emulsions using the same energy input, while the standard deviations of the emulsions processed on a Microfluidizer® processor (0.1 – 2.6) were much lower than those of the homogenized emulsions (3.8 – 14.8)
Instability and phase separation of emulsions and suspensions are critical challenges faced by research and production teams, as most technologies cannot produce the particle size distribution necessary to reach product goals.
To overcome these issues, Microfluidizer® processors use unique fixed-geometry interaction chambers to reduce particle sizes uniformly and to a level unmatched by other methods. This enables customers to optimize formulations for maximum stability, and to enjoy the cost efficiencies offered by products with a prolonged shelf life.
Compared to a high pressure homogenizer, the use of a Microfluidizer® processor usually allows customers to reduce the number of passes needed to reach particle size goals.
In addition they are able to simplify the downstream processing steps as well, both of which have cost benefits.
Pharmaceutical applications, such as vaccine adjuvants, are often nanoemulsions requiring sterile filtration, and uniformly reducing particles to less than 200 nm significantly reduces the required filter area.
Biotechnology company CORIXA was able to reduce average particle size and tighten the distribution, to make sterile filtration possible.
Scaleup from the lab equipment to full-scale production units is guaranteed, bringing cost benefits to production volumes.
This is achieved by the fact that the same interaction chambers are used on both units - resulting in consistent quality and scalability.
Enhancements such as translucent appearances for food or cosmetics products are more efficiently attainable with Microfluidics.